Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

LAA Closure Devices: Reaching Critical Mass?

Executive Summary

Transcatheter LAA closure devices are starting to amass the level of data required to demonstrate their safety and effectiveness, and, if all goes well, the long-awaited FDA approval of the first such device – Boston Scientific’s Watchman – could finally occur sometme next year. Although LAA closure devices have already taken off in some European countries, US physicians continue to struggle with lingering uncertainties, about the learning curve, procedural safety and how LAA closure will stack up against newer anticoagulant drugs. Regardless of how these issues are eventually resolved, industry leaders see a big opportunity for a successful device in the LAA closure space, with market estimates of $1 billion considered conservative by some.

You may also be interested in...



FDA Approves Abbott’s Amplatzer Amulet LAA Occluder To Compete With Boston Scientific’s Watchman

Amplatzer Amulet is a percutaneous transcatheter device designed to prevent thrombus embolization from the left-atrial appendage in people with nonvalvular atrial fibrillation.

News Briefs: DePuy ASR Settlement; Tandem Diabetes IPO; AtriCure Trial

DePuy settles bulk of U.S. ASR suits. Tandem Diabetes closes $138 million IPO. AtriCure gets go-ahead for new AtriClip stroke. More news.

Will Watchman Prevail With FDA? Boston Scientific’s LAA Closure Trial Raises Questions, Controversy

The PREVAIL study of Boston Scientific’s Watchman left atrial appendage (LAA) closure device was primarily positive, but will it be enough to win FDA approval for the device?

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT035516

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel